on monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of severe-to-moderate hemophilia A that it co-developed and licensed. Pfizer (NYSE: PFE).
Pfizer has decided to terminate its global collaboration and licensing agreement Between the two parties. Sangamo intends to explore all options for developing the program, including searching for a potential new cooperation partner.
Read also: The US Food and Drug Administration approved Pfizer’s second hemophilia drug within six months
In July 2024, Pfizer announced key results from the Phase 3 Avene trial of gyroctocogene vitilparvovec, which showed that the trial met key primary and secondary objectives of superiority. compared to prevention.
“We believe it is well positioned for regulatory submissions and potential commercialization,” said Sandy Macri, CEO of Sangamo Therapeutics. “Although we are surprised and extremely disappointed by Pfizer’s decision to end our collaboration so close to the anticipated BLA and MAA submissions…”
The collaboration and licensing agreement with Pfizer will be terminated effective April 21, 2025. All trial participants will continue to be monitored as planned during the transition period.
Sangamo believes that its recently announced partnerships with… Roche Holding AG (OTC:RHHBY) Genentech and Estellas Pharma Company (OTC:ALPMF) (OTC:ALPMY) and advanced business development discussions for its Fabry gene therapy program will allow it to chart a path forward for its neurogenomic medicine pipeline.
The Company is preparing to begin the expected enrollment of patients in the Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy in mid-2025 and the expected submission of a clinical trial authorization application for the prion disease program in the fourth quarter of 2025, each subject to securing additional funding.
Price action: SGMO stock fell 54.70% to $1,106 during the pre-market session at last check on Tuesday.
Read next:
Next: Transform your trading with unique market trading ideas and tools from Benzinga Edge. Click now to access unique insights That can put you ahead in today’s competitive market.
Get the latest stock analysis from Benzinga?
This article Sangamo Therapeutics shares decline as Pfizer terminates hemophilia gene therapy agreement Originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments are closed, but trackbacks and pingbacks are open.